Clozapine-balancing the body and the mind.

[1]  J. MacCabe,et al.  Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis , 2021, The British Journal of Psychiatry.

[2]  A. Tanskanen,et al.  20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20) , 2020, World psychiatry : official journal of the World Psychiatric Association.

[3]  D. Cohen,et al.  Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy , 2020, The Australian and New Zealand journal of psychiatry.

[4]  C. Correll,et al.  Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1–12.5 Years , 2019, Schizophrenia bulletin.

[5]  M. Large,et al.  Meta‐analysis examining the epidemiology of clozapine‐associated neutropenia , 2018, Acta psychiatrica Scandinavica.

[6]  D. Siskind,et al.  The impact of clozapine on hospital use: a systematic review and meta‐analysis , 2017, Acta psychiatrica Scandinavica.

[7]  H. Möller,et al.  Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. , 2017, The American journal of psychiatry.

[8]  D. Siskind,et al.  Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis , 2016, British Journal of Psychiatry.

[9]  Alexandra G. Smith,et al.  Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network , 2011, British Journal of Cancer.